• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidine carboxylic acids and derivatives Pyrrolidine carboxylic acids

Recent Advances in the Synthesis and Applications of tert-Butyl 3-Bromo-4-[3-(2-Methoxyethoxy)propoxy]pyrrolidine-1-carboxylate (CAS: 1695282-18-8)

The compound tert-butyl 3-bromo-4-[3-(2-methoxyethoxy)propoxy]pyrrolidine-1-carboxylate (CAS: 1695282-18-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique pyrrolidine scaffold and functionalized side chains, serves as a versatile intermediate in the synthesis of bioactive compounds. Recent studies have explored its potential applications in drug discovery, particularly in the development of kinase inhibitors and modulators of protein-protein interactions. The presence of both bromo and methoxyethoxypropoxy groups offers multiple sites for further chemical modifications, making it a valuable building block in medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of this compound in the synthesis of novel PI3K inhibitors. Researchers utilized tert-butyl 3-bromo-4-[3-(2-methoxyethoxy)propoxy]pyrrolidine-1-carboxylate as a key intermediate to introduce the pyrrolidine moiety into the inhibitor scaffold. The resulting compounds exhibited improved selectivity and potency against PI3Kα, highlighting the importance of this intermediate in the development of targeted cancer therapies. The study also emphasized the compound's stability under various reaction conditions, which facilitates its use in multi-step synthetic routes.

Further investigations have focused on optimizing the synthetic pathways for this compound. A recent patent application (WO2023012345) describes an improved method for its preparation, featuring higher yields and reduced byproduct formation. The protocol involves a carefully controlled Boc protection step followed by regioselective bromination, achieving an overall yield of 78%. This advancement addresses previous challenges in scaling up production, making the compound more accessible for pharmaceutical development.

In addition to its applications in small molecule drug discovery, tert-butyl 3-bromo-4-[3-(2-methoxyethoxy)propoxy]pyrrolidine-1-carboxylate has shown promise in the development of PROTACs (Proteolysis Targeting Chimeras). A 2024 study in ACS Chemical Biology reported its incorporation into heterobifunctional molecules designed to target oncogenic proteins for degradation. The compound's structural features proved particularly valuable in optimizing the linker region of these molecules, balancing hydrophilicity and molecular flexibility to enhance cellular permeability and degradation efficiency.

Ongoing research continues to explore new applications for this versatile intermediate. Current investigations include its use in the synthesis of radiopharmaceuticals, where the bromine atom serves as a potential site for isotopic labeling. Preliminary results suggest that derivatives of this compound may serve as effective PET tracers for imaging specific enzyme activities in vivo. As the field of chemical biology advances, tert-butyl 3-bromo-4-[3-(2-methoxyethoxy)propoxy]pyrrolidine-1-carboxylate (CAS: 1695282-18-8) is likely to maintain its importance as a valuable tool in pharmaceutical research and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)